PCV Vaccination in HIV Patients with CD4 <180

Key Guideline Recommendations

• The Infectious Diseases Society of America (IDSA) recommends PCV13 for all HIV-infected patients aged ≥2 years, with no CD4 count exclusion criteria, which is a strong recommendation with low to moderate quality evidence 1, 3
• The IDSA guidelines specifically state that PPSV23 should be given to HIV-infected adults with CD4 counts <200 cells/mm³, though this is a weak recommendation with low quality evidence 1

Vaccination Sequence for Your Patient

• Administer PCV13 first to your patient with CD4 <180 cells/mm³ 1

Critical Distinction: Inactivated vs Live Vaccines

• Live vaccines, such as MMR, Varicella, and Yellow fever vaccines, are contraindicated when CD4 <200 cells/mm³ in adults, according to the IDSA guidelines 2, 5, 6
• PCV13 is an inactivated vaccine and does not carry the safety risks associated with live vaccines in severely immunocompromised patients 4

Common Pitfall to Avoid

• The IDSA guidelines advise against confusing the CD4 <200 cells/mm³ contraindication for live vaccines with inactivated vaccines like PCV13, and recommend administering inactivated vaccines according to standard schedules regardless of immune status 2, 4